All In Biotech

Drug Trial Radar · NCT07129252

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Nov 26, 2025

Primary completion

Aug 2027

Study completion Aug 2029

Sponsor

Lead sponsor
Crinetics Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Aug 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.

Conditions

  • SST2-positive Neuroendocrine Neoplasms
  • Neuroendocrine Tumors
  • Neuroendocrine Neoplasm

Interventions

  • CRN09682Drug

    Study drug CRN09682 intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (Dose Escalation) Incidence and severity of DLTs.Time frame: From first dose through Day 21.
  2. (Dose Escalation) Incidence and severity of AEs and SAEs at each dose level and incidence of AEs leading to discontinuation from study drug.Time frame: From first dose of study drug to 30 days after the last dose.
  3. (Dose Expansion) Nature, incidence, and severity of AEs and SAEs at the Expansion Dose.Time frame: From first dose of study drug to 30 days after the last dose.
  4. (Dose Expansion) Interruptions at the Expansion Dose.Time frame: At Day 1 of each cycle through study completion, approximately 2 years.

Locations

27 sites in 2 countries. Site status is shown where the registry gives one.

  • Crinetics Study Site

    Phoenix, Arizona

  • Crinetics Study Site

    Duarte, California

  • Crinetics Study Site

    Newport Beach, California

  • Crinetics Study Site

    Orange, California

  • Crinetics Study Site

    San Francisco, California

  • Crinetics Study Site

    Aurora, Colorado

  • Crinetics Study Site

    Denver, Colorado

  • Crinetics Study Site

    New Haven, Connecticut

  • Crinetics Study Site

    Atlanta, Georgia

  • Crinetics Study Site

    Lexington, Kentucky

  • Crinetics Study Site

    Metairie, Louisiana

  • Crinetics Study Site

    Detroit, Michigan

  • Crinetics Study Site

    Grand Rapids, Michigan

  • Crinetics Study Site

    Rochester, Minnesota

  • Crinetics Study Site

    New York, New York

  • Crinetics Study Site

    Philadelphia, Pennsylvania

  • Crinetics Study Site

    Philadelphia, Pennsylvania

  • Crinetics Study Site

    Austin, Texas

  • Crinetics Study Site

    Houston, Texas

  • Crinetics Study Site

    Irving, Texas

  • Crinetics Study Site

    Salt Lake City, Utah

  • Crinetics Study Site

    Charlottesville, Virginia

  • Crinetics Study Site

    Fairfax, Virginia

  • Crinetics Study Site

    Barcelona, Spain

  • Crinetics Study Site

    Barcelona, Spain

  • Crinetics Study Site

    Madrid, Spain

  • Crinetics Study Site

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.